Italian Absorb Registry

NCT ID: NCT02298413

Last Updated: 2016-02-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1520 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2021-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators aim at evaluating the long-term (5-year) clinical outcome following Absorb BVS implantation in a real world, all-comers population of consecutive patients, as treated according to the indications, techniques and protocols used in the participating institutions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Long-term data after implantation of coronary BVS is scarce, especially in subgroups of patients with diabetes or chronic kidney disease, and in those with complex coronary lesions and/or multivessel disease.

Although the use of BVS is very promising in younger patients with one or more of the above characteristics, evidence of benefit is not available.

The BVS-RAI Registry is a spontaneous initiative of a group of Italian interventional cardiologists who are interested in assessing the results of their interventional practice with BVS, by sharing data.

The BVS-RAI Registry has been created in joint-venture with Centro di Ricerche Farmacologiche e Biomediche "Mario Negri Sud", and is not recipient of funding or benefits originating from the BVS manufacturer or seller. BVS devices are regularly purchased by the participating centres.

Each participating centre is willing to input data of all consecutive patients treated with BVS, with a minimum of 50, and to report on follow-up for at least 5 years. Patient recruitment is not directed per protocol, nor is it rewarded. Patients who give informed consent are included in the BVS-RAI Registry after BVS implant has been performed following the indications, techniques and protocols used in each of the participating institutions.

Baseline patient clinical data, with special attention to biochemistry and drug treatment in patients with diabetes and CKD, as well as angiographic and intravascular imaging data are entered into a web-based Case Report Form.

Follow-up data from outpatient visits or phone interviews, subsequent admissions and coronary angiograms following the protocols being used in each of the participating institutions are prospectively collected and entered into the database.

All data in the CRF is visible to all registered participants at all times. Endpoints are: target lesion and target vessel failure, BVS thrombosis, new revascularisation, myocardial infarction and death. Documentation of those events is required for adjudication by an independent committee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCI with Absorb scaffold

Implantation of biovascular scaffold during PCI

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

biovascular resorbable scaffold

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Successful implantation of 1 or more coronary BVS
* Age \<75 years
* Patient's informed consent

Exclusion Criteria

* None
Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fatebenefratelli and Ophthalmic Hospital

OTHER

Sponsor Role collaborator

Bolognini Hospital

UNKNOWN

Sponsor Role collaborator

Ospedale Regionale di Aosta

UNKNOWN

Sponsor Role collaborator

Ospedali Riuniti di Ancona

UNKNOWN

Sponsor Role collaborator

S. Giacomo Hospital

OTHER

Sponsor Role collaborator

Azienda U.L.S.S n.9 Ospedale di Treviso Ca Foncello

UNKNOWN

Sponsor Role collaborator

Ospedale San Bortolo di Vicenza

OTHER

Sponsor Role collaborator

Azienda Ospedaliera Brotzu

OTHER

Sponsor Role collaborator

San Giuseppe Moscati Hospital

OTHER

Sponsor Role collaborator

Azienda Sanitaria Locale USL 13 Ospedale Mazzoni di Ascoli Piceno

UNKNOWN

Sponsor Role collaborator

S. Andrea Hospital

OTHER

Sponsor Role collaborator

Ospedale Monaldi di Napoli

UNKNOWN

Sponsor Role collaborator

Azienda Ospedaliera di Padova

OTHER

Sponsor Role collaborator

Ospedale della Misericordia di Grosseto

UNKNOWN

Sponsor Role collaborator

Ospedale Santa Corona di Pietra Ligure

UNKNOWN

Sponsor Role collaborator

Istituto Di Ricerche Farmacologiche Mario Negri

OTHER

Sponsor Role collaborator

Ospedale Santa Croce-Carle Cuneo

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dr Giuseppe Steffenino

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alfonso Ielasi, MD

Role: PRINCIPAL_INVESTIGATOR

AO Seriate

Bernardo Cortese, MD

Role: PRINCIPAL_INVESTIGATOR

AO Fatebenefratelli

Donatella Corrado, PhD

Role: PRINCIPAL_INVESTIGATOR

Istituto Di Ricerche Farmacologiche Mario Negri

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

SSD Emodinamica Dip Cardiovasc ASO S.Croce

Cuneo, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Cortese B, Ielasi A, Moscarella E, Loi B, Tarantini G, Pisano F, Durante A, Pasquetto G, Colombo A, Tumminello G, Moretti L, Calabro P, Mazzarotto P, Varricchio A, Tespili M, Latini RA, Defilippi G, Corrado D, Steffenino G; RAI Investigators. Thirty-Day Outcomes After Unrestricted Implantation of Bioresorbable Vascular Scaffold (from the Prospective RAI Registry). Am J Cardiol. 2017 Jun 15;119(12):1924-1930. doi: 10.1016/j.amjcard.2017.03.017. Epub 2017 Mar 29.

Reference Type DERIVED
PMID: 28438304 (View on PubMed)

Cortese B, Ielasi A, Varricchio A, Tarantini G, LaVecchia L, Pisano F, Facchin M, Gistri R, D'Urbano M, Lucci V, Loi B, Tumminello G, Colombo A, Limbruno U, Nicolino A, Calzolari D, Tognoni G, Defilippi G, Buccheri D, Tespili M, Corrado D, Steffenino G; BVS-RAI investigators. Registro Absorb Italiano (BVS-RAI): an investigators-owned and -directed, open, prospective registry of consecutive patients treated with the Absorb BVS: study design. Cardiovasc Revasc Med. 2015 Sep;16(6):340-3. doi: 10.1016/j.carrev.2015.05.010. Epub 2015 Jun 3.

Reference Type DERIVED
PMID: 26100975 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RAI-Registro Absorb Italiano

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.